Stable depot system for prolonged release of protein or peptide drugs, e.g. insulin, comprising phosphatidyl choline, cholesterol and cationic lipids

摘要

A depot system (I), especially for retarded drug release, comprises liposomes containing protein and/or peptide active agent(s), saturated synthetic phosphatidyl choline(s) (PC's), cholesterol and cationic lipid(s), is new. A depot system (I), especially for retarded drug release, comprises liposomes containing: (a) protein and/or peptide active agent(s); (b) saturated synthetic phosphatidyl choline(s) (PC's) selected from dimyristoyl, dipalmitoyl and distearoyl PC's; (c) cholesterol at 35-50 mol. %; and (d) cationic lipid(s) selected from 3beta -(N-(N,N'-dimethylaminoethane)-carbamoyl)-cholesterol (DAC-Chol), cholesteryl 3beta -N-(dimethylaminoethane)-carbamate (DC-Chol), N-(1-(2,3-dimyristoyloxy)-propyl)-N,N,N-trimethylammonium salt (DMTAP), N-(1-(2,3-dipalmitoyloxy)-propyl)-N,N,N-trimethylammonium salt (DPTAP) and N-(1-(2,3-dioleoyloxy)-propyl)-N,N,N-trimethylammonium salt (DOTAP)). Independent claims are included for: (1) the use of depot systems as above for administration of certain active agents other than proteins and/or peptides; and (2) (I) in kit form, optionally together with information for combining the contents of the kit.